The Defense Advanced Research Projects Agency (DARPA) is seeking support for commercialization of technologies to be developed under the upcoming Resuscitation and Prevention of Ischemia-Induced Dysfunction (RAPIID) program. The purpose of this announcement is to notify the community of the RAPIID commercialization goals, initiate dialogue to address program needs, and share the timetable for full proposal submission. This special notice is released under the current DARPA BTO Office Wide Broad Agency Announcement (BAA) HR001126S0003, titled “Biological Technologies.”